Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Ранг среди акций #25864
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Цена акции
$1.21
Рыночная капитализация
$45.55M
Изменение (1 день)
-2.43%
Изменение (1 год)
-34.60%
Страна
US
Торговля Metagenomi, Inc. Common Stock (MGX)

Категория

Коэффициент P/S для Metagenomi, Inc. Common Stock (MGX)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Metagenomi, Inc. Common Stock, текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Metagenomi, Inc. Common Stock с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US